Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estabelecimento de biomarcadores e parâmetros clínicos na distrofia miotônica tipo 1 (END-DM1)

2 de novembro de 2026 atualizado por: Virginia Commonwealth University

Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogeneity going forward.

Funding Source- FDA OOPD

Visão geral do estudo

Status

Recrutamento

Descrição detalhada

Approximately 700 adult participants (18 to 70 years old, inclusive) with DM1 will be enrolled at 15 centers (up to 70 patients will be recruited at each site). No treatment will be administered as part of this study. Participants will receive standard of care as determined by the investigators. Study visits occur at baseline/0 months, 12 months, and 24 months. Few restrictions are placed on participation in the study because the investigators aim to capture the full spectrum of disease severity.

Muscle biopsy sub-study: Studies of splicing biomarkers in muscle biopsy samples will be conducted on a subset of 95 participants. These participants will have an additional study visit at 3 months.

Longitudinal muscle biopsy sub-study: Up to 30 individuals who have had a prior muscle biopsy as part of a DMCRN study will be asked to undergo another biopsy greater than 24 months after the prior biopsy. These participants will have an additional ad hoc biopsy visit.

COVID-19 sub-study: To evaluate severity of illness and response to COVID-19 vaccination in DM1 patients compared to corresponding data available about the general population, END-DM1 study participants will be asked to complete a one-time survey about COVID-19 experiences. A subset of those participants' blood samples will be analyzed to understand immunoglobulin response to infection and vaccination in DM1 patients.

Actigraphy sub-study: To assess daily physical activity in individuals with DM1 and evaluate physical activity changes over a 12-24 month period related to disease progression, a subset of participants will be asked to wear a small, wireless activity monitor while performing functional assessments described in the main study. Those participants will be asked to wear the activity monitor for 7 days following their research visit. Those participants will be asked to complete additional questionnaires.

Handheld Dynamometry sub-study: To evaluate additional muscle strength methods, a subset of participants will be asked to complete additional strength testing using either the MEDup or MicroFET handheld dynamometry device on the same day as their END-DM1 main study visit. Those participants will be asked to return to the clinic for a second visit within 10 days of the END-DM1 study visit to repeat the handheld dynamometry assessments and complete additional strength measures.

Tipo de estudo

Observacional

Inscrição (Estimado)

700

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • München, Alemanha
        • Recrutamento
        • Friedrich Baur Institute, Ludwig-Maximilians-Universität München
        • Contato:
        • Investigador principal:
          • Benedikt Schoser, FEAN
        • Contato:
      • Québec, Canadá
        • Ativo, não recrutando
        • Université de Sherbrooke
    • California
      • La Jolla, California, Estados Unidos, 92703
      • Los Angeles, California, Estados Unidos, 90095
        • Recrutamento
        • University of California, Los Angeles
        • Investigador principal:
          • Perry Shieh, MD, PhD
        • Contato:
    • Colorado
      • Denver, Colorado, Estados Unidos, 80204
    • Florida
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Recrutamento
        • Kansas University Medical Center
        • Investigador principal:
          • Jeffrey Statland, MD
        • Contato:
        • Contato:
    • New York
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Houston Methodist Neurological Institute
        • Investigador principal:
          • Erika P. Greene
        • Contato:
    • Virginia
      • Milan, Itália
        • Concluído
        • Centro Clinico NeMO
      • Auckland, Nova Zelândia
      • London, Reino Unido
      • London, Reino Unido
        • Recrutamento
        • St. George's, University of London
        • Contato:
        • Investigador principal:
          • Emma Matthews

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra de Probabilidade

População do estudo

DM1 has a prevalence rate of approximately 1 per 2,300. There are no expected gender differences. Both men and women will be selected for this study.

Children with DM1 are not included in this project because the pathophysiological basis of congenital and childhood DM1 appears to be mechanistically distinct.

Descrição

Inclusion criteria:

  • Age 18 to 70 (inclusive)
  • Competent to provide informed consent
  • Clinical diagnosis of DM1 based on research criteria1 or positive genetic test
  • Comment: The clinical research criteria require myotonia, muscle weakness in a characteristic distribution, and history of similar findings in a first degree relative. Genetic testing confirmed the diagnosis of DM1 in > 99% of individuals who satisfied these criteria.2

Exclusion criteria:

  • Symptomatic renal or liver disease, uncontrolled diabetes or thyroid disorder, or active malignancy other than skin cancer.
  • Current alcohol or substance abuse
  • Concurrent enrollment in clinical trial for DM1, or participation in trial within 6 months of entry.
  • Concurrent pregnancy or planned pregnancy during the course of the study.
  • Concurrent medical condition that would, in the opinion of the investigator or clinical evaluator, compromise performance on study measures.
  • Note: non-ambulatory participants are not excluded, but are limited to <15% of enrollment.

Inclusion criteria for participants in the muscle biopsy sub-study:

• Of the 95 patients undergoing the tibialis anterior muscle biopsy, at least half will have at least moderate weakness of ankle dorsiflexion, defined as MRC score ≤ 4+. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy. Approximately 10 patients at each site will undergo the muscle biopsy.

Exclusion criteria for 95 participants in the muscle biopsy sub-study:

  • Known CTG repeat expansion size less than 100 repeats, unless there are clear cut signs of limb weakness and muscle wasting. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy.
  • Use of anticoagulant such as warfarin or a direct oral anticoagulant (e.g. dabigatran) due to the increased risk of bleeding.
  • Use of aspirin or non-steroidal anti-inflammatory agents should be discontinued 3 days prior to the biopsy procedure, if possible.
  • Platelet count <50,000 (if known) due to the increased risk of bleeding.
  • History of a bleeding disorder due to the increased risk of bleeding.
  • Advanced wasting of tibialis anterior (TA) muscle that precludes needle muscle biopsy in order to ensure that a sample taken would be of muscle and not just fat and fascia.
  • Previous muscle biopsy of either TA in order to provide muscle tissue samples of non-biopsied muscles.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: OTHER
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Study Visits

Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in ambulation over 24 months as measured by the 10 meter walk (m/s).
Prazo: 12 and 24 months

10 meter walk will be measured (m/s)

12 and 24 months
Change in respiratory function over 24 months as measured by spirometry, specifically the supine forced vital capacity (FVC).
Prazo: 12 and 24 months

Supine forced vital capacity (% predicted)

12 and 24 months
Percent splicing of DM1-affected splice events
Prazo: 3 months

RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI)

3 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Longitudinal Muscle Biopsy Sub-study: Characterization of RNA splicing measures over a prolonged period of time (>24 months)
Prazo: 24 months

RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI)

24 months
Longitudinal Muscle Biopsy Sub-study: Characterization of functional endpoints over a prolonged period of time (>24 months)
Prazo: 24 months

10-meter walk/run, grip strength, ADF (ankle dorsiflexion) strength, supine FVC (forced vital capacity)

24 months
COVID-19 Sub-study: Data from DM1 patients or caregivers about COVID-19 illness and vaccination experience, severity of illness and response to vaccination in DM1 patients compared to corresponding data available about the general population.
Prazo: 24 months

To evaluate the severity and rate of COVID-19 infection in patients with DM1 compared to the general population symptomatic response to COVID-19 vaccination in DM1 patients

24 months
COVID-19 Sub-study: Immunoglobulin profile and measles titers, and COVID-19 IgG titers
Prazo: 24 months

To understand immunoglobulin response to infection and vaccination in DM1 patients

24 months
Actigraphy Sub-study: Feasibility of measuring daily physical activity in individuals with DM1 in a multi-site study
Prazo: 24 months

Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit to evaluate whether this type of activity monitoring is feasible in future trials.

24 months
Actigraphy Sub-study: Objective daily physical activity using wireless accelerometry (ActiGraph), and comparison to normative values and patient reported physical activity.
Prazo: 24 months

Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit and report physical activity, to establish physical activity data in the DM1 population.

24 months
Actigraphy Sub-study: Physical activity changes over a 12-24 month period related to disease progression.
Prazo: 24 months

Participants will wear the wireless activity monitor during the functional and strength measures, and complete additional study questionnaires at their regular END-DM1 study visits.

24 months
Handheld Dynamometry Sub-study: Inter-rater reliability, standard error of measurement, and minimal detectable change of Maximal Isometric Muscle Strength force values obtained with the MEDup and MicroFET handheld dynamometers in adults with DM1
Prazo: 24 months

Participants will be assessed using either the MEDup or MicroFET handheld dynamometer on the same day as an END-DM1 main study visit. Participants will complete a second visit +/- 10 days from that visit where HHD will be assessed using the same HHD method (either MEDup or MicroFET) used at the HHD visit. Additional functional and strength assessments will be captured at this visit.

24 months
Handheld Dynamometry Sub-study: Comparison of quantitative muscle strength testing feasibility and validity between MEDup and MicroFET with the existing Fixed-QMT currently used in the END-DM1 study protocol.
Prazo: 24 months

Data captured for MEDup and MicroFET will be compared to data collected using the Fixed-QMT measures in the main END-DM1 study.

24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de janeiro de 2019

Conclusão Primária (Estimado)

1 de dezembro de 2026

Conclusão do estudo (Estimado)

1 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

2 de junho de 2019

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de junho de 2019

Primeira postagem (Real)

11 de junho de 2019

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Aggregated and deidentified data will be shared with qualified investigators upon majority approval of the DMCRN investigators.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever